Select Medical (SEM) Financials

$14.38 -0.11 (-0.76%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$14.39 +0.01 (+0.07%)

As of 05/23/2025 07:09 PM Eastern

Annual Income Statements for Select Medical

This table shows Select Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	214	243	159	402	259	148	138	177	115	131
Consolidated Net Income / (Loss)	297	300	198	500	345	201	177	221	125	136
Net Income / (Loss) Continuing Operations	130	110	19	500	345	201	177	221	125	136
Total Pre-Tax Income	175	140	35	630	456	265	236	202	181	208
Total Operating Income	268	267	145	714	568	472	417	356	300	275
Total Gross Profit	634	572	401	919	821	813	740	630	552	472
Total Revenue	5,187	4,826	4,609	6,205	5,532	5,454	5,081	4,365	4,217	3,743
Operating Revenue	5,187	4,826	4,609	6,205	5,532	5,454	5,081	4,365	4,217	3,743
Total Cost of Revenue	4,553	4,254	4,208	5,285	4,710	4,641	4,341	3,735	3,665	3,271
Operating Cost of Revenue	4,553	4,254	4,208	5,285	4,710	4,641	4,341	3,735	3,665	3,212
Total Operating Expenses	365	304	257	206	254	341	323	274	252	197
Selling, General & Admin Expense	226	170	153	147	138	128	121	114	107	92
Depreciation Expense	143	136	132	203	206	213	202	160	145	105
Other Operating Expenses / (Income)	-3.41	-1.52	-28	-144	-90	0.00	0.00	-	-	-
Total Other Income / (Expense), net	-94	-128	-109	-84	-111	-207	-182	-153	-119	-66
Interest Expense	157	169	137	136	153	239	213	174	182	113
Interest & Investment Income	64	41	28	50	29	25	22	21	20	17
Income Tax Expense	45	29	17	130	112	64	59	-18	55	72
Net Income / (Loss) Discontinued Operations	167	189	179	-	-	-	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	83	56	39	98	86	53	39	43	9.86	5.26
Basic Earnings per Share	$1.66	$1.91	$1.23	$2.98	$1.93	$1.10	$1.02	$1.33	$0.88	$1.00
Weighted Average Basic Shares Outstanding	128.96M	128.36M	127.17M	133.88M	134.84M	134.31M	135.26M	133.20M	131.10M	127.48M
Diluted Earnings per Share	$1.66	$1.91	$1.23	$2.98	$1.93	$1.10	$1.02	$1.33	$0.87	$0.99
Weighted Average Diluted Shares Outstanding	128.96M	128.36M	127.17M	133.88M	134.84M	134.31M	135.26M	133.20M	131.10M	127.75M
Weighted Average Basic & Diluted Shares Outstanding	128.96M	128.36M	127.17M	133.88M	134.84M	134.31M	135.26M	133.20M	131.10M	130.70M
Cash Dividends to Common per Share	$0.50	$0.50	$0.50	$0.38	-	-	-	$0.00	$0.00	$0.10

This table shows Select Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	57	-16	56	78	97	46	48	78	71	28	27
Consolidated Net Income / (Loss)	75	3.76	81	95	117	62	61	92	85	38	38
Net Income / (Loss) Continuing Operations	75	-163	81	95	117	-127	61	92	85	-142	38
Total Pre-Tax Income	96	-214	108	127	154	-169	77	121	111	-179	54
Total Operating Income	113	-225	141	158	194	-173	130	159	151	-172	91
Total Gross Profit	181	-159	237	262	294	-149	223	251	246	-159	174
Total Revenue	1,353	-123	1,761	1,760	1,789	-179	1,666	1,675	1,665	-143	1,568
Operating Revenue	1,353	-123	1,761	1,760	1,789	-179	1,666	1,675	1,665	-143	1,568
Total Cost of Revenue	1,173	37	1,524	1,498	1,495	-31	1,443	1,424	1,419	16	1,394
Operating Cost of Revenue	1,173	37	1,524	1,498	1,495	-31	1,443	1,424	1,419	16	1,394
Total Operating Expenses	68	65	96	104	100	25	93	92	95	12	83
Selling, General & Admin Expense	33	80	47	50	48	44	41	43	42	39	39
Depreciation Expense	35	-15	50	54	54	-19	52	50	52	-21	51
Other Operating Expenses / (Income)	0.00	0.18	-1.30	0.00	-2.28	-0.31	-0.49	-0.73	0.00	-	-8.44
Total Other Income / (Expense), net	-17	11	-33	-31	-40	4.40	-53	-38	-40	-7.36	-37
Interest Expense	29	3.20	66	37	51	6.33	65	49	49	16	45
Interest & Investment Income	13	14	33	6.32	10	11	12	11	8.56	8.34	8.08
Income Tax Expense	21	-51	27	32	36	-42	16	29	26	-37	16
Net Income / (Loss) Discontinued Operations	0.00	-	-	-	-	-	-	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	18	20	25	17	20	16	13	14	14	10	11
Basic Earnings per Share	$0.44	($0.12)	$0.43	$0.60	$0.75	$0.36	$0.38	$0.61	$0.56	$0.22	$0.21
Weighted Average Basic Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Diluted Earnings per Share	$0.44	($0.12)	$0.43	$0.60	$0.75	$0.36	$0.38	$0.61	$0.56	$0.22	$0.21
Weighted Average Diluted Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Weighted Average Basic & Diluted Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Cash Dividends to Common per Share	$0.06	-	$0.13	$0.13	$0.13	-	$0.13	$0.13	$0.13	-	$0.13

This table details how cash moves in and out of Select Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-24	-14	24	-503	241	161	53	24	85	22
Net Cash From Operating Activities	518	582	285	401	1,028	445	494	238	347	417
Net Cash From Continuing Operating Activities	518	582	285	401	1,028	445	494	238	347	419
Net Income / (Loss) Continuing Operations	297	300	198	500	345	201	177	221	125	272
Consolidated Net Income / (Loss)	297	300	198	500	345	201	177	221	125	272
Depreciation Expense	204	209	206	203	206	213	202	160	145	210
Amortization Expense	2.96	2.65	2.27	2.22	2.18	12	13	11	16	19
Non-Cash Adjustments To Reconcile Net Income	102	28	-53	-302	412	41	11	16	-14	84
Changes in Operating Assets and Liabilities, net	-88	43	-68	-1.23	64	-21	92	-169	74	-166
Net Cash From Investing Activities	-231	-268	-226	-257	-115	-317	-697	-193	-554	-2,424
Net Cash From Continuing Investing Activities	-231	-268	-226	-257	-115	-317	-697	-193	-554	-2,427
Purchase of Property, Plant & Equipment	-222	-229	-190	-181	-146	-157	-167	-233	-162	-365
Acquisitions	-13	-39	-44	-103	-52	-160	-537	-40	-477	-2,128
Divestitures	4.26	0.16	8.34	27	83	0.19	6.76	80	84	66
Net Cash From Financing Activities	-311	-327	-35	-647	-672	32	256	-22	292	2,029
Net Cash From Continuing Financing Activities	-311	-327	-35	-647	-672	32	256	-22	291	2,028
Repayment of Debt	-4,811	-3,231	-871	-40	-558	-3,079	-843	-2,164	-1,114	-1,885
Repurchase of Common Equity	-38	-19	-201	-740	-592	-39	-6.84	-4.75	-2.93	-16
Payment of Dividends	-125	-127	-108	-124	-39	-22	-312	-11	-3.74	396
Issuance of Debt	4,322	3,029	1,146	193	510	3,177	1,417	2,156	1,398	3,517
Issuance of Common Equity	16	23	9.53	21	7.56	18	2.93	9.98	-	-
Other Financing Activities, net	325	-1.69	-10	42	0.00	-24	-2.66	-7.88	14	15
Cash Interest Paid	256	272	183	132	155	183	193	149	143	-
Cash Income Taxes Paid	133	89	32	181	109	71	48	65	71	159

This table details how cash moves in and out of Select Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-6.48	-132	80	19	8.61	6.57	-24	17	-14	-10	14
Net Cash From Operating Activities	-3.46	125	181	278	-67	179	116	235	51	13	94
Net Cash From Continuing Operating Activities	-3.46	125	181	278	-67	179	116	235	51	13	94
Net Income / (Loss) Continuing Operations	75	3.76	81	95	117	62	61	92	85	38	38
Consolidated Net Income / (Loss)	75	3.76	81	95	117	62	61	92	85	38	38
Depreciation Expense	35	46	50	54	54	54	52	50	52	52	51
Amortization Expense	0.78	0.68	0.79	0.74	0.75	0.75	0.73	0.61	0.57	0.58	0.57
Non-Cash Adjustments To Reconcile Net Income	14	70	7.66	9.39	14	15	1.51	6.42	4.61	6.21	2.06
Changes in Operating Assets and Liabilities, net	-128	4.89	41	119	-253	48	0.90	86	-91	-84	2.05
Net Cash From Investing Activities	-52	-74	-45	-54	-58	-70	-63	-67	-69	-57	-55
Net Cash From Continuing Investing Activities	-52	-74	-45	-54	-58	-70	-63	-67	-69	-57	-55
Purchase of Property, Plant & Equipment	-52	-63	-51	-56	-53	-61	-50	-60	-59	-55	-42
Acquisitions	0.00	-11	3.68	-0.59	-5.41	-9.08	-13	-7.34	-10	-4.96	-13
Divestitures	0.02	0.02	1.91	2.07	0.27	0.10	0.00	0.04	0.02	-	-
Net Cash From Financing Activities	49	-183	-56	-206	133	-103	-77	-151	3.42	34	-26
Net Cash From Continuing Financing Activities	49	-183	-56	-206	133	-103	-77	-151	3.42	34	-26
Repayment of Debt	-340	-1,835	-2,223	-399	-353	-344	-2,326	-340	-221	-220	-258
Repurchase of Common Equity	-11	-20	-17	-	-	-7.98	-9.54	-	-	-7.79	-15
Payment of Dividends	-23	-40	-34	-22	-29	-25	-47	-32	-24	-18	-38
Issuance of Debt	421	1,877	1,712	220	513	271	2,301	211	246	280	283
Issuance of Common Equity	7.94	-505	515	1.75	4.00	2.47	5.65	12	2.73	2.43	0.14
Other Financing Activities, net	-5.12	341	-9.45	-4.91	-1.74	0.28	-1.50	0.26	-0.72	-1.30	1.96
Cash Interest Paid	24	39	75	53	89	51	88	49	85	40	69
Cash Income Taxes Paid	1.47	30	42	60	0.60	10	36	42	0.34	7.45	8.42

This table presents Select Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	5,608	7,690	7,665	7,360	7,655	7,340	5,964	5,127	4,921	4,389
Total Current Assets	1,020	1,258	1,271	1,139	1,594	1,213	993	921	763	749
Cash & Equivalents	60	53	98	74	577	336	175	123	99	14
Accounts Receivable	821	724	941	889	897	763	707	692	574	604
Current Deferred & Refundable Income Taxes	27	15	32	56	5.69	19	21	31	12	45
Other Current Assets	112	175	200	120	114	96	90	75	78	86
Other Current Nonoperating Assets	0.00	291	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	872	845	1,001	961	943	998	980	913	892	864
Total Noncurrent Assets	3,716	5,587	5,393	5,259	5,118	5,129	3,992	3,294	3,266	2,775
Goodwill	2,332	2,283	3,484	3,449	3,379	3,392	3,321	2,783	2,751	2,315
Intangible Assets	103	105	352	375	388	409	438	327	341	319
Other Noncurrent Operating Assets	1,281	1,159	1,557	1,435	1,351	1,328	234	184	174	142
Other Noncurrent Nonoperating Assets	0.00	2,039	-	-	-	-	-	-	-	-
Total Liabilities & Shareholders' Equity	5,608	7,690	7,665	7,360	7,655	7,340	5,964	5,127	4,921	4,389
Total Liabilities	3,611	6,116	6,275	5,995	6,004	5,437	4,268	3,554	3,593	3,242
Total Current Liabilities	978	1,248	1,155	1,273	1,438	914	705	605	572	729
Short-Term Debt	20	69	44	18	13	25	44	22	14	225
Accounts Payable	752	706	187	234	177	146	147	128	127	137
Other Current Liabilities	205	203	269	355	542	208	25	29	39	29
Other Current Nonoperating Liabilities	0.00	271	30	29	29	34	12	20	22	9.40
Total Noncurrent Liabilities	2,633	4,867	5,120	4,722	4,566	4,522	3,562	2,948	3,021	2,513
Long-Term Debt	1,692	3,584	3,835	3,556	3,389	3,420	3,250	2,678	2,685	2,161
Noncurrent Deferred & Payable Income Tax Liabilities	81	120	170	143	132	148	154	125	199	219
Other Noncurrent Operating Liabilities	860	751	1,115	1,023	1,044	954	159	146	137	133
Other Noncurrent Nonoperating Liabilities	0.00	411	-	-	-	-	-	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	10	26	34	39	398	975	780	641	422	238
Total Equity & Noncontrolling Interests	1,987	1,548	1,357	1,326	1,253	929	916	933	906	909
Total Preferred & Common Equity	1,681	1,288	1,122	1,110	1,060	771	803	823	816	859
Total Common Equity	1,681	1,288	1,122	1,110	1,060	771	803	823	816	859
Common Stock	911	494	452	504	509	491	483	464	444	425
Retained Earnings	770	752	581	593	553	280	320	360	372	435
Accumulated Other Comprehensive Income / (Loss)	0.00	43	89	12	-2.03	0.00	-	-	-	-
Noncontrolling Interest	306	259	235	216	192	158	113	109	90	49

This table presents Select Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	5,696	8,003	7,875	7,858	7,684	7,702	7,700	7,555
Total Current Assets	1,092	1,404	1,365	1,440	1,276	1,304	1,314	1,217
Cash & Equivalents	53	191	111	93	77	101	84	108
Accounts Receivable	908	1,060	1,078	1,135	944	965	997	909
Current Deferred & Refundable Income Taxes	6.57	8.67	8.45	9.03	23	17	17	19
Other Current Assets	124	144	167	204	232	222	216	181
Plant, Property, & Equipment, net	895	1,040	1,031	1,025	1,007	1,004	987	957
Total Noncurrent Assets	3,709	5,558	5,480	5,393	5,401	5,393	5,399	5,380
Goodwill	2,332	3,555	3,525	3,517	3,505	3,486	3,485	3,479
Intangible Assets	103	313	317	324	337	347	347	358
Other Noncurrent Operating Assets	1,274	1,690	1,637	1,552	1,560	1,560	1,568	1,543
Total Liabilities & Shareholders' Equity	5,696	8,003	7,875	7,858	7,684	7,702	7,700	7,555
Total Liabilities	3,650	5,702	6,139	6,192	6,134	6,166	6,247	6,187
Total Current Liabilities	945	1,246	1,257	1,184	1,166	1,188	1,186	1,197
Short-Term Debt	28	43	46	60	35	57	114	43
Accounts Payable	714	939	939	850	183	187	174	207
Other Current Liabilities	202	264	272	274	273	273	271	269
Total Noncurrent Liabilities	2,705	4,457	4,882	5,008	4,968	4,978	5,061	4,990
Long-Term Debt	1,767	3,099	3,594	3,759	3,695	3,695	3,767	3,750
Noncurrent Deferred & Payable Income Tax Liabilities	75	96	98	134	147	156	163	162
Other Noncurrent Operating Liabilities	863	1,262	1,190	1,115	1,125	1,126	1,131	1,078
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	9.02	30	30	28	27	34	34	34
Total Equity & Noncontrolling Interests	2,037	2,270	1,707	1,638	1,523	1,502	1,418	1,335
Total Preferred & Common Equity	1,719	1,915	1,417	1,367	1,268	1,246	1,170	1,106
Total Common Equity	1,719	1,915	1,417	1,367	1,268	1,246	1,170	1,106
Common Stock	909	859	519	506	482	474	462	445
Retained Earnings	814	1,056	891	831	723	697	635	570
Accumulated Other Comprehensive Income / (Loss)	-3.11	0.00	5.78	31	63	75	73	91
Noncontrolling Interest	318	355	290	270	256	256	248	229

This table displays calculated financial ratios and metrics derived from Select Medical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.48%	4.70%	-25.71%	12.16%	1.43%	7.33%	16.40%	3.50%	12.68%	22.11%
EBITDA Growth	-0.72%	35.65%	-61.68%	16.87%	12.15%	9.59%	21.65%	4.67%	-5.63%	48.03%
EBIT Growth	0.40%	84.62%	-79.78%	23.43%	21.24%	12.23%	19.80%	3.89%	12.50%	7.02%
NOPAT Growth	-5.55%	177.59%	-86.57%	32.23%	19.60%	14.31%	-19.18%	86.62%	15.92%	0.21%
Net Income Growth	-1.01%	51.36%	-60.39%	45.08%	71.42%	13.61%	-19.81%	76.14%	-7.89%	6.10%
EPS Growth	-13.09%	55.28%	-58.72%	54.40%	75.45%	7.84%	-23.31%	52.87%	-12.12%	8.79%
Operating Cash Flow Growth	-11.03%	104.36%	-29.01%	-60.97%	130.93%	-9.92%	107.53%	-31.30%	-16.85%	144.27%
Free Cash Flow Firm Growth	-95.89%	911.61%	-230.24%	-81.60%	599.13%	140.45%	-304.72%	177.95%	78.55%	-964.54%
Invested Capital Growth	3.46%	-32.20%	6.30%	8.62%	-10.73%	4.55%	15.74%	5.58%	11.98%	50.33%
Revenue Q/Q Growth	-25.56%	-26.73%	-26.98%	1.63%	1.58%	33.31%	0.18%	-18.26%	-1.44%	7.70%
EBITDA Q/Q Growth	-42.22%	-35.05%	-41.36%	-8.29%	6.51%	23.09%	1.20%	-12.45%	-18.12%	71.92%
EBIT Q/Q Growth	-55.81%	-49.34%	-63.26%	-10.46%	9.57%	38.54%	-1.24%	-17.73%	-0.29%	12.62%
NOPAT Q/Q Growth	-57.18%	-48.41%	-76.81%	-6.18%	8.56%	43.28%	-33.78%	39.34%	-1.55%	3.35%
Net Income Q/Q Growth	-16.36%	8.74%	-12.62%	-6.70%	20.47%	40.48%	-38.73%	53.73%	-4.11%	-1.21%
EPS Q/Q Growth	-22.43%	7.91%	0.00%	0.00%	0.00%	5.77%	-35.85%	84.72%	-8.42%	2.06%
Operating Cash Flow Q/Q Growth	-9.44%	40.20%	34.65%	-40.06%	2.89%	17.20%	1.03%	21.61%	-29.86%	499.01%
Free Cash Flow Firm Q/Q Growth	-81.99%	630.27%	-188.07%	-62.96%	2.34%	468.26%	-48.62%	246.59%	6.90%	-1.18%
Invested Capital Q/Q Growth	-30.50%	-32.37%	2.73%	5.12%	-0.61%	-0.77%	-0.68%	0.35%	0.62%	1.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	12.22%	11.84%	8.71%	14.82%	14.85%	14.91%	14.57%	14.43%	13.09%	12.61%
EBITDA Margin	9.16%	9.92%	7.66%	14.84%	14.24%	12.88%	12.62%	12.07%	11.94%	14.25%
Operating Margin	5.17%	5.54%	3.14%	11.50%	10.26%	8.65%	8.21%	8.15%	7.11%	7.34%
EBIT Margin	5.17%	5.54%	3.14%	11.54%	10.49%	8.77%	8.39%	8.15%	8.12%	8.13%
Profit (Net Income) Margin	5.72%	6.21%	4.30%	8.06%	6.23%	3.69%	3.48%	5.05%	2.97%	3.63%
Tax Burden Percent	169.77%	214.52%	561.49%	79.39%	75.49%	75.93%	75.12%	108.98%	69.31%	65.25%
Interest Burden Percent	65.14%	52.28%	24.36%	87.96%	78.70%	55.34%	55.26%	56.90%	52.77%	68.46%
Effective Tax Rate	25.62%	20.94%	47.42%	20.61%	24.51%	24.07%	24.88%	-8.98%	30.69%	34.75%
Return on Invested Capital (ROIC)	5.56%	4.84%	1.51%	12.06%	8.97%	7.26%	6.97%	9.55%	5.56%	6.10%
ROIC Less NNEP Spread (ROIC-NNEP)	10.95%	7.91%	4.83%	9.97%	6.17%	2.24%	2.20%	3.15%	2.26%	3.91%
Return on Net Nonoperating Assets (RNNOA)	11.06%	15.38%	12.87%	21.09%	10.42%	3.91%	3.85%	5.66%	4.57%	7.97%
Return on Equity (ROE)	16.62%	20.22%	14.37%	33.15%	19.39%	11.17%	10.82%	15.21%	10.12%	14.07%
Cash Return on Invested Capital (CROIC)	2.16%	43.22%	-4.60%	3.80%	20.31%	2.81%	-7.62%	4.13%	-5.75%	-34.11%
Operating Return on Assets (OROA)	4.04%	3.48%	1.93%	9.54%	7.74%	7.19%	7.69%	7.08%	7.36%	8.33%
Return on Assets (ROA)	4.46%	3.90%	2.64%	6.66%	4.60%	3.02%	3.19%	4.39%	2.69%	3.72%
Return on Common Equity (ROCE)	13.82%	16.44%	11.64%	23.86%	9.99%	4.88%	5.38%	8.59%	6.85%	11.64%
Return on Equity Simple (ROE_SIMPLE)	17.65%	23.27%	17.65%	45.04%	32.50%	26.08%	22.03%	26.80%	15.36%	15.83%
Net Operating Profit after Tax (NOPAT)	200	211	76	567	429	358	313	388	208	179
NOPAT Margin	3.85%	4.38%	1.65%	9.13%	7.75%	6.57%	6.17%	8.88%	4.93%	4.79%
Net Nonoperating Expense Percent (NNEP)	-5.39%	-3.07%	-3.32%	2.09%	2.80%	5.01%	4.77%	6.41%	3.30%	2.20%
Return On Investment Capital (ROIC_SIMPLE)	5.40%	4.06%	1.45%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	87.78%	88.16%	91.29%	85.18%	85.15%	85.09%	85.43%	85.57%	86.91%	87.39%
SG&A Expenses to Revenue	4.35%	3.53%	3.32%	2.37%	2.50%	2.36%	2.39%	2.61%	2.54%	2.46%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	7.04%	6.31%	5.57%	3.31%	4.59%	6.25%	6.36%	6.28%	5.98%	5.26%
Earnings before Interest and Taxes (EBIT)	268	267	145	716	580	478	426	356	342	304
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	475	479	353	921	788	703	641	527	503	533
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.45	1.27	1.49	3.38	3.31	3.82	2.43	2.70	2.02	1.71
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.47	0.34	0.36	0.60	0.63	0.54	0.38	0.51	0.39	0.39
Price to Earnings (P/E)	11.40	6.70	10.53	9.32	13.53	19.86	14.17	12.53	14.28	11.24
Dividend Yield	95.12%	3.93%	3.79%	1.34%	0.00%	0.00%	0.00%	0.00%	0.00%	3.57%
Earnings Yield	8.77%	14.93%	9.50%	10.73%	7.39%	5.04%	7.06%	7.98%	7.00%	8.90%
Enterprise Value to Invested Capital (EV/IC)	1.21	1.56	1.10	1.53	1.54	1.42	1.24	1.33	1.21	1.17
Enterprise Value to Revenue (EV/Rev)	0.85	1.14	1.24	1.21	1.25	1.32	1.17	1.27	1.13	1.10
Enterprise Value to EBITDA (EV/EBITDA)	9.28	11.53	16.22	8.15	8.78	10.23	9.31	10.53	9.46	7.74
Enterprise Value to EBIT (EV/EBIT)	16.43	20.64	39.55	10.48	11.93	15.03	13.99	15.59	13.90	13.56
Enterprise Value to NOPAT (EV/NOPAT)	22.09	26.11	75.21	13.24	16.15	20.07	19.03	14.31	22.91	23.02
Enterprise Value to Operating Cash Flow (EV/OCF)	8.51	9.48	20.10	18.70	6.73	16.15	12.07	23.30	13.74	9.90
Enterprise Value to Free Cash Flow (EV/FCFF)	56.85	2.93	0.00	42.04	7.14	51.83	0.00	33.12	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.86	2.32	2.79	2.62	2.06	1.81	1.94	1.72	2.03	2.08
Long-Term Debt to Equity	0.85	2.28	2.76	2.61	2.05	1.80	1.92	1.70	2.02	1.88
Financial Leverage	1.01	1.94	2.66	2.12	1.69	1.74	1.75	1.80	2.02	2.04
Leverage Ratio	3.72	5.18	5.45	4.98	4.22	3.70	3.39	3.46	3.76	3.78
Compound Leverage Factor	2.43	2.71	1.33	4.38	3.32	2.05	1.87	1.97	1.99	2.59
Debt to Total Capital	46.15%	69.89%	73.61%	72.36%	67.32%	64.41%	66.00%	63.18%	67.02%	67.54%
Short-Term Debt to Total Capital	0.55%	1.32%	0.84%	0.36%	0.25%	0.47%	0.88%	0.52%	0.34%	6.37%
Long-Term Debt to Total Capital	45.61%	68.57%	72.77%	72.01%	67.07%	63.94%	65.12%	62.66%	66.68%	61.16%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	8.51%	5.47%	5.10%	5.16%	11.69%	21.18%	17.91%	17.55%	12.72%	8.14%
Common Equity to Total Capital	45.33%	24.65%	21.29%	22.47%	20.99%	14.41%	16.09%	19.27%	20.26%	24.32%
Debt to EBITDA	3.60	7.63	10.99	3.88	4.32	4.90	5.14	5.12	5.36	4.47
Net Debt to EBITDA	3.48	7.52	10.72	3.80	3.59	4.43	4.86	4.89	5.16	4.45
Long-Term Debt to EBITDA	3.56	7.49	10.87	3.86	4.30	4.87	5.07	5.08	5.33	4.05
Debt to NOPAT	8.58	17.29	50.97	6.31	7.94	9.61	10.51	6.96	12.99	13.31
Net Debt to NOPAT	8.28	17.04	49.68	6.18	6.59	8.68	9.95	6.65	12.51	13.23
Long-Term Debt to NOPAT	8.48	16.96	50.39	6.28	7.91	9.54	10.37	6.90	12.92	12.05
Altman Z-Score	1.69	1.04	0.95	1.63	1.45	1.39	1.50	1.63	1.51	1.50
Noncontrolling Interest Sharing Ratio	16.84%	18.70%	19.00%	28.04%	48.48%	56.28%	50.27%	43.51%	32.32%	17.29%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.04	1.01	1.10	0.90	1.11	1.33	1.41	1.52	1.33	1.03
Quick Ratio	0.90	0.62	0.90	0.76	1.02	1.20	1.25	1.35	1.18	0.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	78	1,886	-232	178	970	139	-343	168	-215	-1,002
Operating Cash Flow to CapEx	233.09%	253.95%	149.62%	222.24%	702.04%	283.33%	295.43%	102.10%	214.44%	114.11%
Free Cash Flow to Firm to Interest Expense	0.49	11.17	-1.69	1.31	6.34	0.58	-1.61	0.96	-1.18	-8.88
Operating Cash Flow to Interest Expense	3.29	3.45	2.07	2.95	6.72	1.87	2.32	1.37	1.91	3.69
Operating Cash Flow Less CapEx to Interest Expense	1.88	2.09	0.69	1.62	5.76	1.21	1.54	0.03	1.02	0.46
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.78	0.63	0.61	0.83	0.74	0.82	0.92	0.87	0.91	1.02
Accounts Receivable Turnover	6.71	5.80	5.04	6.95	6.67	7.42	7.27	6.90	7.16	7.14
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	6.04	5.23	4.70	6.51	5.70	5.51	5.37	4.84	4.80	5.32
Accounts Payable Turnover	6.25	9.54	20.01	25.72	29.18	31.74	31.58	29.33	27.77	26.60
Days Sales Outstanding (DSO)	54.38	62.98	72.48	52.54	54.75	49.17	50.23	52.91	50.95	51.09
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	58.42	38.28	18.24	14.19	12.51	11.50	11.56	12.45	13.14	13.72
Cash Conversion Cycle (CCC)	-4.04	24.70	54.24	38.35	42.24	37.67	38.67	40.46	37.80	37.37
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,649	3,527	5,202	4,894	4,505	5,047	4,827	4,171	3,950	3,528
Invested Capital Turnover	1.45	1.11	0.91	1.32	1.16	1.10	1.13	1.08	1.13	1.27
Increase / (Decrease) in Invested Capital	122	-1,675	309	388	-541	220	656	220	423	1,181
Enterprise Value (EV)	4,408	5,517	5,724	7,502	6,921	7,190	5,965	5,548	4,761	4,128
Market Capitalization	2,440	1,631	1,674	3,747	3,505	2,948	1,953	2,221	1,649	1,469
Book Value per Share	$12.99	$10.05	$8.84	$8.27	$7.87	$5.74	$5.93	$6.15	$6.16	$6.55
Tangible Book Value per Share	($5.82)	($8.58)	($21.37)	($20.23)	($20.08)	($22.56)	($21.84)	($17.08)	($17.20)	($13.52)
Total Capital	3,709	5,227	5,270	4,939	5,053	5,349	4,990	4,273	4,027	3,533
Total Debt	1,712	3,653	3,880	3,574	3,402	3,445	3,293	2,700	2,699	2,386
Total Long-Term Debt	1,692	3,584	3,835	3,556	3,389	3,420	3,250	2,678	2,685	2,161
Net Debt	1,652	3,601	3,782	3,500	2,825	3,109	3,118	2,577	2,600	2,371
Capital Expenditures (CapEx)	222	229	190	181	146	157	167	233	162	365
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.70	25	63	-190	-409	-12	156	215	106	231
Debt-free Net Working Capital (DFNWC)	62	78	161	-116	168	324	331	338	205	245
Net Working Capital (NWC)	42	9.18	116	-134	156	299	287	315	191	20
Net Nonoperating Expense (NNE)	-97	-88	-122	67	84	157	137	167	83	43
Net Nonoperating Obligations (NNO)	1,652	1,953	3,811	3,529	2,854	3,143	3,130	2,597	2,622	2,381
Total Depreciation and Amortization (D&A)	207	211	208	205	208	224	215	171	161	229
Debt-free, Cash-free Net Working Capital to Revenue	0.05%	0.53%	1.36%	-3.07%	-7.39%	-0.22%	3.07%	4.93%	2.51%	6.16%
Debt-free Net Working Capital to Revenue	1.20%	1.62%	3.48%	-1.87%	3.04%	5.94%	6.52%	7.73%	4.86%	6.55%
Net Working Capital to Revenue	0.81%	0.19%	2.52%	-2.15%	2.81%	5.48%	5.65%	7.23%	4.54%	0.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.66	$1.91	$1.23	$2.98	$0.00	$0.00	$1.02	$1.33	$0.88	$1.00
Adjusted Weighted Average Basic Shares Outstanding	128.96M	128.36M	127.17M	133.88M	0.00	0.00	135.26M	128.96M	127.81M	127.48M
Adjusted Diluted Earnings per Share	$1.66	$1.91	$1.23	$2.98	$0.00	$0.00	$1.02	$1.33	$0.87	$0.99
Adjusted Weighted Average Diluted Shares Outstanding	128.96M	128.36M	127.17M	133.88M	0.00	0.00	135.26M	129.13M	127.97M	127.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	128.96M	128.36M	127.17M	133.88M	0.00	0.00	135.26M	134.10M	132.68M	131.28M
Normalized Net Operating Profit after Tax (NOPAT)	200	211	76	567	429	358	313	249	208	179
Normalized NOPAT Margin	3.85%	4.38%	1.65%	9.13%	7.75%	6.57%	6.17%	5.71%	4.93%	4.79%
Pre Tax Income Margin	3.37%	2.90%	0.77%	10.15%	8.25%	4.85%	4.64%	4.64%	4.29%	5.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.70	1.58	1.05	5.26	3.79	2.00	2.00	2.04	1.88	2.70
NOPAT to Interest Expense	1.27	1.25	0.55	4.17	2.80	1.50	1.47	2.22	1.14	1.59
EBIT Less CapEx to Interest Expense	0.29	0.23	-0.33	3.94	2.83	1.35	1.22	0.70	1.00	-0.54
NOPAT Less CapEx to Interest Expense	-0.14	-0.11	-0.83	2.84	1.84	0.84	0.69	0.89	0.25	-1.65
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	42.00%	42.52%	54.38%	24.74%	11.20%	10.83%	176.06%	4.81%	2.98%	-290.98%
Augmented Payout Ratio	54.78%	48.86%	156.09%	172.78%	183.10%	30.00%	179.92%	6.97%	5.32%	-279.35%

This table displays calculated financial ratios and metrics derived from Select Medical's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.42%	31.60%	5.73%	5.08%	7.44%	-25.42%	6.24%	5.67%	4.09%	-109.16%	2.19%
EBITDA Growth	-14.40%	-50.16%	4.91%	1.30%	21.69%	0.16%	27.58%	21.52%	31.41%	-191.39%	-28.59%
EBIT Growth	-4.83%	-29.53%	8.60%	-0.88%	28.07%	-1.00%	42.08%	31.61%	45.65%	-321.39%	-39.13%
NOPAT Growth	6.00%	-29.53%	2.72%	-2.82%	27.67%	-1.00%	60.89%	30.11%	47.18%	-234.79%	-45.51%
Net Income Growth	-36.22%	-93.92%	33.21%	3.16%	37.43%	63.87%	59.51%	38.63%	52.45%	-43.13%	-61.96%
EPS Growth	-41.33%	-133.33%	13.16%	-1.64%	33.93%	63.64%	80.95%	41.86%	51.35%	0.00%	-63.16%
Operating Cash Flow Growth	94.82%	-30.10%	55.55%	18.44%	-229.64%	1,330.50%	23.42%	36.79%	711.74%	120.65%	-4.74%
Free Cash Flow Firm Growth	3,524.64%	-117.97%	246.99%	245.90%	116.97%	462.40%	86.06%	86.86%	81.70%	-43.33%	-7,566.89%
Invested Capital Growth	-29.74%	3.46%	0.68%	0.93%	2.51%	-32.20%	2.99%	3.34%	4.15%	6.30%	8.79%
Revenue Q/Q Growth	1,203.85%	-106.96%	0.09%	-1.63%	7.83%	-110.76%	-0.53%	0.57%	5.28%	-109.11%	-1.07%
EBITDA Q/Q Growth	183.26%	-192.76%	-9.61%	-14.59%	47.22%	-164.81%	-12.72%	2.59%	46.36%	-182.82%	-16.87%
EBIT Q/Q Growth	150.20%	-259.13%	-10.56%	-18.65%	69.77%	-233.41%	-18.37%	5.12%	74.36%	-287.68%	-24.39%
NOPAT Q/Q Growth	155.72%	-248.25%	-9.94%	-20.41%	54.31%	-217.56%	-14.79%	4.56%	63.71%	-287.27%	-31.09%
Net Income Q/Q Growth	1,889.67%	-95.36%	-14.51%	-19.12%	89.60%	1.61%	-33.79%	7.74%	126.07%	-1.09%	-42.46%
EPS Q/Q Growth	466.67%	-127.91%	-28.33%	-20.00%	108.33%	-5.26%	-37.70%	8.93%	154.55%	4.76%	-51.16%
Operating Cash Flow Q/Q Growth	-102.76%	-30.69%	-34.94%	517.09%	-137.16%	54.24%	-50.46%	356.53%	310.08%	-86.69%	-45.09%
Free Cash Flow Firm Q/Q Growth	705.66%	-495.25%	2.20%	334.29%	-89.39%	3,332.44%	-1.44%	49.49%	60.54%	-24.33%	4.36%
Invested Capital Q/Q Growth	3.82%	-30.50%	-0.28%	-2.35%	4.74%	-32.37%	-0.03%	-0.82%	1.12%	2.73%	0.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	13.34%	0.00%	13.47%	14.87%	16.45%	0.00%	13.40%	14.98%	14.78%	0.00%	11.10%
EBITDA Margin	10.96%	0.00%	10.91%	12.08%	13.91%	0.00%	10.99%	12.53%	12.28%	0.00%	9.15%
Operating Margin	8.33%	0.00%	8.01%	8.97%	10.84%	0.00%	7.80%	9.51%	9.10%	0.00%	5.83%
EBIT Margin	8.33%	0.00%	8.01%	8.97%	10.84%	0.00%	7.80%	9.51%	9.10%	0.00%	5.83%
Profit (Net Income) Margin	5.52%	0.00%	4.60%	5.39%	6.55%	0.00%	3.65%	5.49%	5.12%	0.00%	2.43%
Tax Burden Percent	77.70%	-1.76%	75.14%	74.61%	76.27%	-36.57%	79.44%	76.10%	76.50%	-21.06%	70.15%
Interest Burden Percent	85.31%	95.15%	76.40%	80.49%	79.20%	97.47%	58.91%	75.82%	73.58%	104.29%	59.42%
Effective Tax Rate	22.30%	0.00%	24.86%	25.39%	23.73%	0.00%	20.56%	23.90%	23.50%	0.00%	29.85%
Return on Invested Capital (ROIC)	7.36%	0.00%	8.02%	8.77%	10.54%	0.00%	7.94%	9.15%	8.64%	0.00%	5.32%
ROIC Less NNEP Spread (ROIC-NNEP)	6.89%	0.00%	7.26%	8.14%	9.72%	0.00%	6.79%	8.35%	7.82%	0.00%	4.50%
Return on Net Nonoperating Assets (RNNOA)	10.15%	0.00%	12.47%	17.93%	23.49%	0.00%	17.13%	21.40%	20.35%	0.00%	8.52%
Return on Equity (ROE)	17.51%	0.00%	20.49%	26.70%	34.03%	0.00%	25.07%	30.55%	28.99%	0.00%	13.83%
Cash Return on Invested Capital (CROIC)	39.42%	2.16%	8.23%	7.90%	6.28%	43.22%	5.03%	3.96%	2.60%	-4.60%	-1.66%
Operating Return on Assets (OROA)	6.42%	0.00%	7.12%	7.91%	9.46%	0.00%	6.74%	8.09%	7.64%	0.00%	4.77%
Return on Assets (ROA)	4.25%	0.00%	4.09%	4.75%	5.72%	0.00%	3.16%	4.67%	4.30%	0.00%	1.99%
Return on Common Equity (ROCE)	14.56%	0.00%	16.94%	21.73%	27.69%	0.00%	20.39%	24.57%	23.39%	0.00%	9.27%
Return on Equity Simple (ROE_SIMPLE)	14.79%	0.00%	18.52%	23.62%	24.26%	0.00%	21.74%	20.30%	19.42%	0.00%	20.50%
Net Operating Profit after Tax (NOPAT)	88	-157	106	118	148	-121	103	121	116	-120	64
NOPAT Margin	6.47%	0.00%	6.02%	6.69%	8.27%	0.00%	6.20%	7.24%	6.96%	0.00%	4.09%
Net Nonoperating Expense Percent (NNEP)	0.47%	-8.93%	0.76%	0.64%	0.82%	-6.35%	1.15%	0.79%	0.82%	-4.30%	0.82%
Return On Investment Capital (ROIC_SIMPLE)	2.29%	-4.25%	-	-	-	-2.33%	-	-	-	-2.29%	-
Cost of Revenue to Revenue	86.66%	0.00%	86.53%	85.13%	83.55%	0.00%	86.60%	85.02%	85.22%	0.00%	88.90%
SG&A Expenses to Revenue	2.44%	0.00%	2.69%	2.83%	2.71%	0.00%	2.48%	2.54%	2.54%	0.00%	2.52%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	5.01%	0.00%	5.46%	5.90%	5.60%	0.00%	5.60%	5.48%	5.69%	0.00%	5.26%
Earnings before Interest and Taxes (EBIT)	113	-225	141	158	194	-173	130	159	151	-172	91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	148	-178	192	212	249	-119	183	210	204	-119	143
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.25	1.45	2.37	3.21	2.81	1.27	2.49	3.18	2.73	1.49	2.43
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.41	0.47	0.65	0.66	0.57	0.34	0.48	0.61	0.50	0.36	0.43
Price to Earnings (P/E)	12.39	11.40	16.41	16.89	14.23	6.70	14.04	19.45	17.72	10.53	14.80
Dividend Yield	106.99%	95.12%	1.43%	1.43%	1.67%	3.93%	2.01%	1.60%	1.99%	3.79%	2.35%
Earnings Yield	8.07%	8.77%	6.10%	5.92%	7.03%	14.93%	7.12%	5.14%	5.64%	9.50%	6.76%
Enterprise Value to Invested Capital (EV/IC)	1.11	1.21	1.50	1.59	1.46	1.56	1.36	1.51	1.38	1.10	1.31
Enterprise Value to Revenue (EV/Rev)	0.81	0.85	1.13	1.22	1.16	1.14	1.08	1.22	1.14	1.24	1.05
Enterprise Value to EBITDA (EV/EBITDA)	9.38	9.28	9.57	10.32	9.70	11.53	9.62	11.33	11.03	16.22	11.02
Enterprise Value to EBIT (EV/EBIT)	16.08	16.43	12.96	14.08	13.16	20.64	13.44	16.16	16.15	39.55	16.83
Enterprise Value to NOPAT (EV/NOPAT)	20.52	22.09	16.88	18.13	16.85	26.11	17.31	21.26	21.18	75.21	20.20
Enterprise Value to Operating Cash Flow (EV/OCF)	7.27	8.51	13.76	16.54	16.95	9.48	17.08	20.10	22.07	20.10	31.35
Enterprise Value to Free Cash Flow (EV/FCFF)	2.33	56.85	18.27	20.26	23.49	2.93	27.46	38.90	54.31	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.88	0.86	1.37	2.10	2.29	2.32	2.41	2.44	2.67	2.79	2.77
Long-Term Debt to Equity	0.86	0.85	1.35	2.07	2.26	2.28	2.38	2.41	2.59	2.76	2.74
Financial Leverage	1.47	1.01	1.72	2.20	2.42	1.94	2.52	2.56	2.60	2.66	1.89
Leverage Ratio	3.65	3.72	4.07	4.76	4.99	5.18	5.22	5.29	5.32	5.45	4.60
Compound Leverage Factor	3.12	3.54	3.11	3.83	3.95	5.05	3.08	4.01	3.92	5.69	2.73
Debt to Total Capital	46.74%	46.15%	57.73%	67.70%	69.63%	69.89%	70.64%	70.96%	72.76%	73.61%	73.50%
Short-Term Debt to Total Capital	0.74%	0.55%	0.79%	0.86%	1.10%	1.32%	0.66%	1.08%	2.14%	0.84%	0.84%
Long-Term Debt to Total Capital	46.00%	45.61%	56.94%	66.84%	68.53%	68.57%	69.98%	69.88%	70.63%	72.77%	72.66%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	8.50%	8.51%	7.08%	5.95%	5.45%	5.47%	5.35%	5.48%	5.29%	5.10%	5.08%
Common Equity to Total Capital	44.75%	45.33%	35.19%	26.35%	24.93%	24.65%	24.01%	23.56%	21.94%	21.29%	21.42%
Debt to EBITDA	3.99	3.60	3.82	4.48	4.71	7.63	5.06	5.38	5.88	10.99	6.30
Net Debt to EBITDA	3.87	3.48	3.59	4.34	4.60	7.52	4.96	5.24	5.75	10.72	6.13
Long-Term Debt to EBITDA	3.93	3.56	3.77	4.42	4.64	7.49	5.01	5.30	5.71	10.87	6.23
Debt to NOPAT	8.73	8.58	6.74	7.87	8.18	17.29	9.11	10.10	11.29	50.97	11.56
Net Debt to NOPAT	8.47	8.28	6.33	7.63	7.98	17.04	8.92	9.82	11.05	49.68	11.23
Long-Term Debt to NOPAT	8.59	8.48	6.65	7.77	8.05	16.96	9.02	9.94	10.96	50.39	11.42
Altman Z-Score	1.57	1.40	1.61	1.56	1.50	0.85	1.37	1.44	1.34	0.81	1.24
Noncontrolling Interest Sharing Ratio	16.85%	0.00%	17.34%	18.64%	18.63%	0.00%	18.68%	19.58%	19.32%	0.00%	32.98%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.16	1.04	1.13	1.09	1.22	1.01	1.09	1.10	1.11	1.10	1.02
Quick Ratio	1.02	0.90	1.00	0.95	1.04	0.62	0.88	0.90	0.91	0.90	0.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,691	-279	71	69	16	1,554	-48	-47	-94	-429	-345
Operating Cash Flow to CapEx	-6.61%	197.75%	357.06%	500.74%	-126.99%	296.09%	231.76%	394.59%	87.36%	22.70%	225.01%
Free Cash Flow to Firm to Interest Expense	58.17	-87.20	1.06	1.86	0.31	245.58	-0.74	-0.97	-1.93	-27.30	-7.63
Operating Cash Flow to Interest Expense	-0.12	39.17	2.73	7.50	-1.31	28.37	1.79	4.79	1.06	0.80	2.09
Operating Cash Flow Less CapEx to Interest Expense	-1.92	19.36	1.96	6.00	-2.35	18.79	1.02	3.58	-0.15	-2.72	1.16
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.78	0.89	0.88	0.87	0.63	0.86	0.85	0.84	0.61	0.82
Accounts Receivable Turnover	5.11	6.71	6.95	6.73	6.37	5.80	7.11	6.88	6.60	5.04	6.98
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	5.44	6.04	6.81	6.75	6.75	5.23	6.71	6.62	6.60	4.70	6.67
Accounts Payable Turnover	5.89	6.25	10.63	10.45	11.34	9.54	29.16	26.99	27.23	20.01	27.98
Days Sales Outstanding (DSO)	71.44	54.38	52.49	54.24	57.32	62.98	51.35	53.05	55.29	72.48	52.27
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	61.99	58.42	34.34	34.93	32.18	38.28	12.52	13.52	13.41	18.24	13.04
Cash Conversion Cycle (CCC)	9.45	-4.04	18.15	19.31	25.14	24.70	38.83	39.53	41.89	54.24	39.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,789	3,649	5,251	5,265	5,392	3,527	5,215	5,217	5,260	5,202	5,064
Invested Capital Turnover	1.14	1.45	1.33	1.31	1.27	1.11	1.28	1.26	1.24	0.91	1.30
Increase / (Decrease) in Invested Capital	-1,604	122	35	49	132	-1,675	151	169	210	309	409
Enterprise Value (EV)	4,223	4,408	7,869	8,391	7,862	5,517	7,092	7,903	7,280	5,724	6,631
Market Capitalization	2,154	2,440	4,534	4,542	3,837	1,631	3,156	3,962	3,201	1,674	2,683
Book Value per Share	$13.33	$12.99	$14.73	$10.89	$10.52	$10.05	$9.97	$9.80	$9.20	$8.84	$8.78
Tangible Book Value per Share	($5.54)	($5.82)	($15.02)	($18.66)	($19.03)	($8.58)	($20.24)	($20.35)	($20.92)	($21.37)	($21.70)
Total Capital	3,842	3,709	5,442	5,377	5,485	5,227	5,281	5,289	5,334	5,270	5,162
Total Debt	1,796	1,712	3,142	3,640	3,819	3,653	3,730	3,753	3,881	3,880	3,794
Total Long-Term Debt	1,767	1,692	3,099	3,594	3,759	3,584	3,695	3,695	3,767	3,835	3,750
Net Debt	1,743	1,652	2,950	3,529	3,726	3,601	3,653	3,651	3,797	3,782	3,686
Capital Expenditures (CapEx)	52	63	51	56	53	61	50	60	59	55	42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	123	2.70	9.81	43	224	25	68	72	158	63	-44
Debt-free Net Working Capital (DFNWC)	176	62	201	155	316	78	145	173	242	161	64
Net Working Capital (NWC)	147	42	158	108	256	9.18	110	116	128	116	21
Net Nonoperating Expense (NNE)	13	-161	25	23	31	-183	42	29	31	-158	26
Net Nonoperating Obligations (NNO)	1,743	1,652	2,950	3,529	3,726	1,953	3,665	3,681	3,807	3,811	3,696
Total Depreciation and Amortization (D&A)	36	46	51	55	55	55	53	51	53	53	52
Debt-free, Cash-free Net Working Capital to Revenue	2.35%	0.05%	0.14%	0.63%	3.29%	0.53%	1.03%	1.11%	2.47%	1.36%	-0.70%
Debt-free Net Working Capital to Revenue	3.37%	1.20%	2.89%	2.25%	4.66%	1.62%	2.20%	2.67%	3.78%	3.48%	1.01%
Net Working Capital to Revenue	2.83%	0.81%	2.27%	1.57%	3.77%	0.19%	1.67%	1.79%	2.00%	2.52%	0.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.44	($0.12)	$0.43	$0.60	$0.75	$0.36	$0.38	$0.61	$0.56	$0.22	$0.21
Adjusted Weighted Average Basic Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Adjusted Diluted Earnings per Share	$0.44	($0.12)	$0.43	$0.60	$0.75	$0.36	$0.38	$0.61	$0.56	$0.22	$0.21
Adjusted Weighted Average Diluted Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	128.54M	128.96M	129.47M	130.02M	130.03M	128.36M	128.21M	127.14M	127.13M	127.17M	126.98M
Normalized Net Operating Profit after Tax (NOPAT)	88	-157	106	118	148	-121	103	121	116	-120	64
Normalized NOPAT Margin	6.47%	0.00%	6.02%	6.69%	8.27%	0.00%	6.20%	7.24%	6.96%	0.00%	4.09%
Pre Tax Income Margin	7.11%	0.00%	6.12%	7.22%	8.59%	0.00%	4.60%	7.21%	6.69%	0.00%	3.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.88	-70.14	2.13	4.25	3.82	-27.41	2.00	3.25	3.12	-10.93	2.02
NOPAT to Interest Expense	3.01	-49.10	1.60	3.17	2.91	-19.19	1.59	2.47	2.39	-7.65	1.42
EBIT Less CapEx to Interest Expense	2.08	-89.95	1.36	2.76	2.79	-36.99	1.23	2.03	1.91	-14.45	1.10
NOPAT Less CapEx to Interest Expense	1.21	-68.91	0.83	1.68	1.88	-28.77	0.82	1.26	1.17	-11.17	0.49
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	46.62%	42.00%	30.73%	36.53%	39.94%	42.52%	43.92%	44.33%	46.00%	54.38%	56.84%
Augmented Payout Ratio	66.01%	54.78%	38.03%	42.18%	39.94%	48.86%	50.76%	53.93%	46.00%	156.09%	439.72%

Frequently Asked Questions About Select Medical's Financials

When does Select Medical's financial year end?

According to the most recent income statement we have on file, Select Medical's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Select Medical's net income changed over the last 9 years?

Select Medical's net income appears to be on an upward trend, with a most recent value of $296.70 million in 2024, rising from $136.00 million in 2015. The previous period was $299.73 million in 2023. See where experts think Select Medical is headed by visiting Select Medical's forecast page.

What is Select Medical's operating income?

Select Medical's total operating income in 2024 was $268.32 million, based on the following breakdown:

Total Gross Profit: $633.64 million
Total Operating Expenses: $365.33 million

How has Select Medical revenue changed over the last 9 years?

Over the last 9 years, Select Medical's total revenue changed from $3.74 billion in 2015 to $5.19 billion in 2024, a change of 38.6%.

How much debt does Select Medical have?

Select Medical's total liabilities were at $3.61 billion at the end of 2024, a 41.0% decrease from 2023, and a 11.4% increase since 2015.

How much cash does Select Medical have?

In the past 9 years, Select Medical's cash and equivalents has ranged from $14.44 million in 2015 to $577.06 million in 2020, and is currently $59.69 million as of their latest financial filing in 2024.

How has Select Medical's book value per share changed over the last 9 years?

Over the last 9 years, Select Medical's book value per share changed from 6.55 in 2015 to 12.99 in 2024, a change of 98.3%.

Related Companies

This page (NYSE:SEM) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Select Medical (SEM) Financials

Frequently Asked Questions About Select Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Select Medical (SEM) Financials

Annual Income Statements for Select Medical

Quarterly Income Statements for Select Medical

Annual Cash Flow Statements for Select Medical

Quarterly Cash Flow Statements for Select Medical

Annual Balance Sheets for Select Medical

Quarterly Balance Sheets for Select Medical

Annual Metrics And Ratios for Select Medical

Quarterly Metrics And Ratios for Select Medical

Frequently Asked Questions About Select Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools